Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
In the video, Shelley, a 70-year-old diagnosed with acute myeloid leukemia after her chronic myelomonocytic leukemia progressed, shares her cancer journey and how participating in a clinical trial…
NEW YORK (Reuters Health) – Depending on the treatment they received, survivors of childhood cancer may require long-term follow-up because of an elevated risk of symptomatic cardiac events,…
NEW YORK (Reuters Health) – Daily low-dose aspirin reduces not only cardiovascular mortality but also nonvascular mortality – and cancer mortality in particular — after relatively short duration…
NEW YORK (Reuters Health) – A systematic review and meta-analysis provides “reasonable” support for the current practice of giving adjuvant therapy to patients with resected biliary tract cancer…
NEW YORK (Reuters Health) – Progression-free survival (PFS) is significantly longer in women with recurrent ovarian cancer when bevacizumab is added to chemotherapy, a multicenter team reports in…
NEW YORK (Reuters Health) – Cancer patients given pegfilgrastim experience less bone pain if they take naproxen 500 mg twice daily for about a week, according to the…
NEW YORK (Reuters Health) – Adding trastuzumab (Herceptin) to standard chemotherapy for HER2-positive early breast cancer significantly reduces recurrence risk and improves overall survival, but it also increases…
NEW YORK (Reuters Health) – Adding cladribine to the standard induction regimen for adults with acute myeloid leukemia (AML) increases the complete remission rate and consequent survival, a…
NEW YORK (Reuters Health) – Adding bevacizumab (Avastin, Genentech) to standard carboplatin and paclitaxel chemotherapy offers little clinical benefit in patients aged 65 and older with non-small cell…
NEW YORK (Reuters Health) – Older patients with small localized kidney tumors treated with partial nephrectomy live longer than those treated with radical nephrectomy, a new study suggests.…
NEW YORK (Reuters Health) – A meta-analysis of individual patient data found no differences in overall survival, progression-free survival, and objective response rate between cisplatin- and carboplatin-based chemotherapy…
